Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Peptide aptamers: recent developments for cancer therapy.

Corina Borghouts¹, Christian Kunz, Bernd Groner

¹Georg-Speyer-Haus Institute for Biomedical Research, Paul-Ehrlich-Strasse 42-44, D-60596 Frankfurt am Main, Germany.

Expert Opinion on Biological Therapy

|June 15, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prospective systematic classification of causes of death in the course of multiple myeloma.

Blood cancer journal·2025

Same author

CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study.

Leukemia·2024

Same author

Selective haematological cancer eradication with preserved haematopoiesis.

Nature·2024

Same author

Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis.

Oncology and therapy·2024

Same author

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.

The Lancet. Haematology·2024

Same author

A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2023

Peptide aptamers offer a novel approach to cancer therapy by inhibiting key signaling pathways. This review explores their isolation, delivery, and therapeutic potential in preclinical cancer models.

Area of Science:

Oncology
Molecular Biology
Drug Development

Background:

Significant advancements in understanding oncogenesis have identified novel signaling pathways crucial for tumor cell survival.
Aberrant signaling in cancer cells presents unique therapeutic targets for novel anticancer agents.

Purpose of the Study:

To review methods for isolating and delivering peptide aptamers.
To discuss the achievements and potential of peptide aptamers as cancer therapeutics.

Main Methods:

Selection and isolation of specific peptide aptamers targeting protein domains.
Strategies for modifying, stabilizing, and delivering peptide aptamers in vivo.
Evaluation of peptide aptamer efficacy in preclinical cancer models.

Related Experiment Videos

Main Results:

Peptide aptamers can be designed to specifically recognize and interfere with target protein functions.
Advances in peptide modification and delivery enhance their stability and therapeutic application.
Successful preclinical applications demonstrate the potential of peptide aptamers in various cancer systems.

Conclusions:

Peptide aptamers represent a promising class of molecules for cancer drug development.
Further research into their modification, delivery, and clinical application is warranted.
Peptide aptamers hold significant potential as novel therapeutics for cancer treatment.